Microparticles for Inhalational Delivery of Antipseudomonal Antibiotics
Journal Title: The AAPS Journal - Year 2008, Vol 10, Issue 2
Abstract
Chronic pseudomonal bronchopulmonary infections in cystic fibrosis patients are frequently controlled with inhaled antibiotics. Dry-powder inhalable antibiotics are an attractive alternative to nebulized medications. We produced and evaluated microparticles composed of dipalmitoylphosphatidylcholine, albumin, and lactose as a model system for intrapulmonary delivery of ceftazidime, ciprofloxacin, and several combinations of the two, none of which is presently available for inhalation. Microparticles containing one or both antibiotics were prepared by spray-drying. Their Anderson cascade impactor deposition profiles showed 10–30% fine particle fractions of the nominal dose. Microparticles containing varying amounts of each antibiotic showed statistically different deposition profiles. Aerodynamics and deposition of microparticles co-encapsulating both antibiotics were similar to those of single-drug microparticles with the same proportion of ciprofloxacin alone. The antipseudomonal activities of microparticles co-encapsulating half of the 50% effective concentration (EC50) of both ceftazidime and ciprofloxacin (5 mg of particles containing 5% ceftazidime and 10% ciprofloxacin) were at least additive compared to particles containing the EC50 of each antibiotic separately (5 mg of particles containing 10% ceftazidime or 5 mg of particles containing 20% ciprofloxacin). Co-encapsulation of the antibiotics in microparticles ensures co-deposition at desired ratios, improves the particles’ aerodynamics and fine particle fraction, as compared to microparticles with equivalent amounts of ceftazidime alone, and achieves additive antipseudomonal activity.
Authors and Affiliations
Michael D. Tsifansky, Yoon Yeo, Oleg V. Evgenov, Evangelia Bellas, John Benjamin, Daniel S. Kohane
Keywords
Related Articles
- EP ID EP681547
- DOI 10.1208/s12248-008-9033-8
- Views 72
- Downloads 0
Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination
The online version of this article (doi:10.1208/s12248-016-9889-y) contains supplementary material, which is available to authorized users.
Headway and Hurdles in the Clinical Development of Dietary Phytochemicals for Cancer Therapy and Prevention: Lessons Learned from Vitamin A Derivatives
Accumulating epidemiologic and preclinical evidence support the pharmacologic use of a variety of dietary chemicals for the prevention and treatment of cancer. However, it will be challenging to translate these findings...
Alginate–Chitosan–PLGA Composite Microspheres Enabling Single-Shot Hepatitis B Vaccination
Hepatitis B vaccination typically requires a multi-dose administration protocol over a course of 3–6 months. Aiming at developing a single-shot formulation for hepatitis B vaccine (hepatitis B surface ant...
Role of bioactivation in drug-induced hypersensitivity reactions
Drug-induced hypersensitivity reactions are a major problem in both clinical treatment and drug development. This review covers recent developments in our understanding of the pathogenic mechanisms involved, with special...
Brain tissue lipidomics: Direct probing using matrix-assisted laser desorption/ionization mass spectrometry
Lipidomics is the new frontier in biomolecular structural studies. Not only are lipids the main components in membranes that define the contours of the cell and its organelles, but they are also used for storage. Lipids...